Labcorp Holdings (LH) announced the commercial release of its H5 bird flu molecular test to support the diagnosis of human H5 bird flu infections.
The test, developed with the support of the Centers for Disease Control and Prevention, is available in the US for physicians to order for suspected H5N1 infections in people, the company said Tuesday in a statement.
Health-care providers can order the test for suspected cases using nasopharyngeal swab specimens to analyze polymerase chain reactions, the company said.
The US faces a multistate poultry and dairy cow outbreak of H5 bird flu with recent cases found in industry workers.
Labcorp shares rose 1% in recent Tuesday trading.
Price: 231.81, Change: +2.19, Percent Change: +0.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。